Birchview Capital »

Regenxbio Inc equity us cm shares owned by Birchview Capital

Quarter-by-quarter ownership of Regenxbio Inc equity us cm (RGNX) shares owned by Birchview Capital from 13F filings

Historical chart of Birchview Capital investment in Regenxbio Inc equity us cm

Tip: Access up to 7 years of quarterly data

All positions including Regenxbio Inc equity us cm held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Regenxbio Inc equity us cm by Birchview Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $555k 66k 8.38

More positions owned by Birchview Capital

Kla Corporation Com New (KLAC)
Bristol Myers Squibb (BMY)
Compass Therapeutics (CMPX)
Lam Research Corporation Com New (LRCX)
Stoke Therapeutics (STOK)
Encana Corporation (OVV)
Intellia Therapeutics (NTLA)
Structure Therapeutics Spons Adr (GPCR)
Solid Biosciences Com New (SLDB)
Prothena Corp SHS (PRTA)
Biodesix
ACADIA Pharmaceuticals (ACAD)
Protagonist Therapeutics (PTGX)
Neurocrine Biosciences (NBIX)
Olema Pharmaceuticals (OLMA)

View all positions for Birchview Capital

Top funds holding Regenxbio Inc equity us cm

BlackRock
Redmile Group
Vanguard Group
State Street Corporation
Morgan Stanley
Vanguard Capital Management
Goldman Sachs Group
Integral Health Asset Management
Geode Capital Management
AQR Capital Management
Vanguard Portfolio Management
Dimensional Fund Advisors
Assenagon Asset Management
Nuveen
Two Sigma Investments

View all funds holding Regenxbio Inc equity us cm